South Korea
· Delayed Price · Currency is KRW SK bioscience Co.,Ltd. Company Description
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally.
Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children.
The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States.
SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
| Country | South Korea |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 984 |
| CEO | Jae-Yong Ahn |
Contact Details
Address: 310, Pangyo-ro Seongnam-si, 13494 South Korea | |
| Phone | 82 2 2008 2200 |
| Website | skbioscience.co.kr |
Stock Details
| Ticker Symbol | 302440 |
| Exchange | Korea Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7302440003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jae-Yong Ahn | Chief Executive Officer, President and Director |
| Dr. Sally Choe | Head of Global Clinical Development and Regulatory Affairs |